Shakthi Kumaran Ramasamy

All Publications

• ChatGPT and the Reshaping of Radiology Training RADIOLOGY Ramasamy, S. 2023; 307 (5)

  View details for Web of Science ID 001038622300013

• Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration. Journal of visualized experiments : JoVE Ramasamy, S. K., Roudi, R., Morakote, W., Adams, L. C., Pisani, L. J., Moseley, M., Daldrup-Link, H. E. 2023

  Abstract

  T2* relaxometry is one of the established methods to measure the effect of superparamagnetic iron oxide nanoparticles on tumor tissues with magnetic resonance imaging (MRI). Iron oxide nanoparticles shorten the T1, T2, and T2* relaxation times of tumors. While the T1 effect is variable based on the size and composition of the nanoparticles, the T2 and T2* effects are usually predominant, and T2* measurements are the most time-efficient in a clinical context. Here, we present our approach to measuring tumor T2* relaxation times, using multi-echo gradient echo sequences, external software, and a standardized protocol for creating a T2* map with scanner-independent software. This facilitates the comparison of imaging data from different clinical scanners, different vendors, and co-clinical research work (i.e., tumor T2* data obtained in mouse models and patients). Once the software is installed, the T2 Fit Map plugin needs to be installed from the plugin manager. This protocol provides step-by-step procedural details, from importing the multi-echo gradient echo sequences into the software, to creating color-coded T2* maps and measuring tumor T2* relaxation times. The protocol can be applied to solid tumors in any body part and has been validated based on preclinical imaging data and clinical data in patients. This could facilitate tumor T2* measurements for multi-center clinical trials and improve the standardization and reproducibility of tumor T2* measurements in co-clinical and multi-center data analyses.

  View details for DOI 10.3791/64773

  View details for PubMedID 37318243

• Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art. AJR. American journal of roentgenology Adams, L. C., Jayapal, P., Ramasamy, S. K., Morakote, W., Yeom, K., Baratto, L., Daldrup-Link, H. E. 2022

  Abstract

  Ferumoxytol is an ultrasmall iron oxide nanoparticle, originally approved in 2009 by the FDA for IV treatment of iron deficiency in adults with chronic kidney disease. Subsequently, its off-label use as an MRI contrast agent has increased in clinical practice, particularly in pediatric patients in North America. Unlike conventional MRI contrast agents that are based on the rare earth metal gadolinium [gadolinium-based contrast agents (GBCAs)], ferumoxytol is biodegradable and carries no potential risk of nephrogenic systemic fibrosis. At FDA-approved doses, ferumoxytol demonstrates no long-term tissue retention in patients with intact iron metabolism. Ferumoxytol provides unique MRI properties including long-lasting vascular retention (facilitating high-quality vascular imaging) and retention in reticuloendothelial system tissues, thereby supporting a variety of applications beyond those possible with GBCAs. This Clinical Perspective describes clinical and early translational applications of ferumoxytol-enhanced MRI in children and young adults through off-label use for a variety of settings, including vascular, cardiac, and cancer imaging, drawing on the authors' institutional experience. In addition, we describe current preclinical and clinical research advances using ferumoxytol with regard to cellular and molecular imaging, and also as a novel potential cancer therapeutic agent.

  View details for DOI 10.2214/AJR.22.28453

  View details for PubMedID 36197052

• Women in academic radiology: comparative analysis of leadership in interventional and diagnostic radiology Society of Interventional Radiology (SIR) Annual Scientific Meeting Tafreshi, S., Le, R., Ramasamy, S., Choudhury, P., Goldman, D., Hamilton, B. 2022: S131

  View details for DOI 10.1016/j.jvir.2022.03.366

• Enhancement conspicuity of Hepatocellular Carcinoma is decreased in the presence of Transjugular Intrahepatic Portosystemic Shunts Global Embolization Symposium & Technologies (GEST) Ramasamy, S., Ploussard, B., Lovrec, P., Ness, J., Sullivan, I., Jawahar, A., Molvar, C. 2022: e23

  View details for DOI 10.1016/j.jvir.2022.04.022

• Transvenous embolization of cerebrospinal fluid–venous fistula (CVF): a systematic review Global Embolization Symposium & Technologies (GEST) Ramasamy, S. 2022: e48

  View details for DOI 10.1016/j.jvir.2022.04.022

• Endovascular Treatment of Infected Superior Mesenteric Artery Aneurysm: A Case Report and Systematic Review The International Symposium on Endovascular Therapy (ISET) Ramasamy, S., Ahmed, O. 2022: e9

  View details for DOI 10.1016/j.jvir.2021.12.001

• Endovascular treatment of Infected SMA Aneurysm: A case report and systematic review. The International Symposium on Endovascular Therapy (ISET) Ramasamy, S., Ahmed, O. 2022: e9

  View details for DOI 10.1016/j.jvir.2021.12.001

• Segmental Yttrium-90 Radioembolization as an Initial Treatment for Solitary Unresectable HCC The Arab Journal of Interventional Radiology Rothenberger, N., Yu, Q., Ramasamy, S., Van Ha, T., Zangan,, ., Navuluri, R., Ahmed, O. 2022; 06 (02)

  View details for DOI 10.1055/s-0042-1758698